Clovis Oncology, Inc.
CLVSDelisted Dec 29, 2022- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001466301
Clovis Oncology, Inc. was delisted on Dec 29, 2022; its insiders filed their last Form 4 on Nov 3, 2022; 103 institutions reported holding it in 13F filings for Q3 2022, worth $42.6M in total; no superinvestor held it.
13F holders, Q3 2022
Institutional positions in Clovis Oncology, Inc. as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
CLVS is no longer listed, so this page shows Q3 2022. 13F filings for later quarters list far fewer holders.
- Institutional holders
- 103
- −12 vs. Q2 2022
- Shares held
- 35.8M
- −6.47M (−15.3%) vs. Q2 2022
- Total value
- $42.6M
- −$33.5M (−44.0%) vs. Q2 2022
- New holders
- 12
- 24 more added
- Sold out
- 24
- 37 more reduced
1 institution that held it in Q2 2022 haven't filed for Q3 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CLVS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 1 | $11.0K |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 2 | $520.2K |
| Q4 2022 | 15 | $20.1K |
| Q3 2022 | 103 | $42.6M |
| Q2 2022 | 116 | $76.0M |
| Q1 2022 | 153 | $111.7M |
| Q4 2021 | 154 | $176.8M |
| Q3 2021 | 159 | $274.0M |
| Q2 2021 | 161 | $319.9M |
| Q1 2021 | 165 | $347.3M |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding Clovis Oncology, Inc.; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Kozak & Associates, Inc. | 140 | $0 | 0.00% | 00.0% | Unchanged |
| Quent Capital, LLC | 231 | $0 | 0.00% | 00.0% | Unchanged |
| IFP Advisors, Inc | 10,000 | – | – | +10,000 | New |
| Ergoteles LLC | 0 | $0 | 0.00% | −707,300−100.0% | Sold out |
| Group One Trading, L.P. | 0 | $0 | 0.00% | −237,835−100.0% | Sold out |
| Caption Management, LLC | 0 | $0 | 0.00% | −182,455−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −130,830−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −99,358−100.0% | Sold out |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −74,712−100.0% | Sold out |
| Two Sigma Advisers, LP | 0 | $0 | 0.00% | −49,400−100.0% | Sold out |
| Wolverine Trading, LLC | 0 | $0 | 0.00% | −45,133−100.0% | Sold out |
| Balyasny Asset Management LLC | 0 | $0 | 0.00% | −26,841−100.0% | Sold out |
| First Republic Investment Management, Inc. | 0 | $0 | 0.00% | −22,000−100.0% | Sold out |
| Teacher Retirement System of Texas | 0 | $0 | 0.00% | −18,624−100.0% | Sold out |
| Ameriprise Financial Inc | 0 | $0 | 0.00% | −15,330−100.0% | Sold out |
| Kalos Management, Inc. | 0 | $0 | 0.00% | −10,500−100.0% | Sold out |
| Y-Intercept (Hong Kong) Ltd | 0 | $0 | 0.00% | −11,630−100.0% | Sold out |
| Cubist Systematic Strategies, LLC | 0 | $0 | 0.00% | −10,367−100.0% | Sold out |
| blooom, inc. | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| Prospera Financial Services Inc | 0 | $0 | 0.00% | −9,150−100.0% | Sold out |
| Spire Wealth Management | 0 | $0 | 0.00% | −4,000−100.0% | Sold out |
| New York State Common Retirement Fund | 0 | $0 | 0.00% | −1,182−100.0% | Sold out |
| Point72 Hong Kong Ltd | 0 | $0 | 0.00% | −1,267−100.0% | Sold out |
| Huntington National Bank | 0 | $0 | 0.00% | −800−100.0% | Sold out |
| Captrust Financial Advisors | 0 | $0 | 0.00% | −30−100.0% | Sold out |
| Cypress Capital Management LLC (WY) | 0 | $0 | 0.00% | −200−100.0% | Sold out |
| Elequin Capital LP | 0 | $0 | 0.00% | −12−100.0% | Sold out |
| Exane Derivatives | – | – | – | – | Not filed |